SPOTLIGHT: Wyeth gains EU approval for hemophilia drug


Wyeth got the EU's approval to sell a new-and-improved version of its BeneFix hemophilia B treatment. The new version comes in a more concentrated form for faster infusion, and it's available in a larger-dosage vial. Wyeth recently took over marketing of the drug, developed by Genetics Institute, from Baxter. Genetics Institute has been a Wyeth subsidiary since 1996. Release

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.